Caxton Associates LLP Makes New $730,000 Investment in Bio-Rad Laboratories, Inc. $BIO

Key Points

• Caxton Associates LLP acquired a new position in Bio-Rad Laboratories, purchasing 2,998 shares valued at approximately $730,000 during the first quarter.
• Several institutional investors raised their stakes in Bio-Rad, with First Pacific Advisors LP increasing its position by 136.0% to 372,555 shares worth around $90.7 million.
• Bio-Rad Laboratories reported a quarterly earnings per share of $2.61, surpassing analyst expectations of $1.93, with a revenue of $651.6 million for the same period.

Caxton Associates LLP bought a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 2,998 shares of the medical research company's stock, valued at approximately $730,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Quarry LP purchased a new stake in Bio-Rad Laboratories in the first quarter valued at $29,000. Curat Global LLC acquired a new stake in shares of Bio-Rad Laboratories in the 1st quarter worth approximately $34,000. Allworth Financial LP raised its stake in shares of Bio-Rad Laboratories by 260.0% during the 1st quarter. Allworth Financial LP now owns 144 shares of the medical research company's stock worth $36,000 after buying an additional 104 shares during the last quarter. Headlands Technologies LLC grew its holdings in Bio-Rad Laboratories by 64.1% during the 1st quarter. Headlands Technologies LLC now owns 356 shares of the medical research company's stock valued at $87,000 after buying an additional 139 shares during the last quarter. Finally, Twin Tree Management LP acquired a new stake in shares of Bio-Rad Laboratories during the first quarter worth $87,000. Institutional investors and hedge funds own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Performance

BIO traded down $5.58 on Friday, hitting $280.32. The company had a trading volume of 242,366 shares, compared to its average volume of 217,635. The company's fifty day moving average price is $272.32 and its 200 day moving average price is $252.08. Bio-Rad Laboratories, Inc. has a 1-year low of $211.43 and a 1-year high of $387.99. The stock has a market cap of $7.59 billion, a price-to-earnings ratio of 23.90 and a beta of 0.95. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.68. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The firm had revenue of $651.60 million during the quarter, compared to analyst estimates of $614.82 million. During the same quarter in the prior year, the business posted $3.11 earnings per share. The company's quarterly revenue was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on BIO. Wall Street Zen lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Friday, August 22nd. Wells Fargo & Company raised their price target on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Royal Bank Of Canada boosted their price target on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an "outperform" rating in a research report on Friday, August 1st. Finally, Zacks Research upgraded shares of Bio-Rad Laboratories from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 26th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $333.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.